LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

LLY

1,045.35

-1.18%↓

JNJ

205.34

-0.12%↓

ABBV

224.4

-0.21%↓

UNH

324.92

+0.43%↑

AZN

90.2

-0.31%↓

Search

Incyte Corp

Cerrado

SectorSanidad

101.47 -0.5

Resumen

Variación precio

24h

Actual

Mínimo

100.51

Máximo

103.27

Métricas clave

By Trading Economics

Ingresos

19M

424M

Ventas

150M

1.4B

P/B

Media del Sector

17.295

80.03

BPA

2.26

Margen de beneficios

31.052

Empleados

2,617

EBITDA

-75M

506M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

-7.59% downside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

1.9B

20B

Apertura anterior

101.97

Cierre anterior

101.47

Puntuación técnica

By Trading Central

Confianza

Bullish Evidence

Incyte Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 dic 2025, 17:29 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

Laurentian Bank Shares Hit Two-Year High on Plans for Break-Up, Takeover

2 dic 2025, 16:21 UTC

Ganancias

Scotiabank Aiming for Earnings Growth After Capital Markets Buoy Results in Latest Quarter -- Update

2 dic 2025, 16:18 UTC

Ganancias

Correction to Scotiabank Quarterly Earnings Buoyed Article

2 dic 2025, 23:53 UTC

Charlas de Mercado

Nikkei May Rise After Gains on Wall Street -- Market Talk

2 dic 2025, 22:48 UTC

Ganancias

Marvell's Stock Soars On Data Center Forecast -- Barrons.com

2 dic 2025, 22:12 UTC

Charlas de Mercado

Australian 3Q GDP To Show Modest Recovery In Play -- Market Talk

2 dic 2025, 22:03 UTC

Charlas de Mercado

Minerals 260's Resource Upgrade Looks Impressive -- Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 dic 2025, 22:00 UTC

Charlas de Mercado

Fletcher Building Loses Bull Due to Tame Housing-Market Recovery -- Market Talk

2 dic 2025, 21:56 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 21:44 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 21:38 UTC

Charlas de Mercado

Sky Network TV Has Path to Grow Dividend by 33% -- Market Talk

2 dic 2025, 21:19 UTC

Ganancias

Marvell's Stock Drops As Outlook Fails to Impress -- Barrons.com

2 dic 2025, 20:06 UTC

Charlas de Mercado

Oil Futures Fall Amid Russia-Ukraine Peace Talks -- Market Talk

2 dic 2025, 19:55 UTC

Charlas de Mercado

Natural Gas Futures Fall Amid Uncertain Weather Forecasts -- Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Global Equities Roundup: Market Talk

2 dic 2025, 19:53 UTC

Charlas de Mercado
Ganancias

Scotiabank ROE Target Viewed as Possibly Conservative -- Market Talk

2 dic 2025, 19:24 UTC

Charlas de Mercado

Analysts Project Uptick in U.S. Ethanol Stocks -- Market Talk

2 dic 2025, 19:06 UTC

Charlas de Mercado

Precious Metals Step Back After Silver Sets Record -- Market Talk

2 dic 2025, 18:27 UTC

Adquisiciones, fusiones, absorciones

Kraken to Acquire Backed Finance AG

2 dic 2025, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

2 dic 2025, 17:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

2 dic 2025, 15:17 UTC

Charlas de Mercado

Natural Gas Extends Gains Amid Cold Weather -- Market Talk

2 dic 2025, 14:47 UTC

Charlas de Mercado

BOE Likely to Cut Rates Further, Weakening Sterling -- Market Talk

2 dic 2025, 14:38 UTC

Charlas de Mercado

Silver Steps Back From Record Levels -- Market Talk

2 dic 2025, 14:31 UTC

Charlas de Mercado
Ganancias

Scotiabank Strong Quarter Driven By Capital Markets Growth -- Market Talk

Comparación entre iguales

Cambio de precio

Incyte Corp previsión

Precio Objetivo

By TipRanks

-7.59% descenso

Estimación a 12 Meses

Media 96.53 USD  -7.59%

Máximo 125 USD

Mínimo 73 USD

De acuerdo con 19 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Incyte Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

19 ratings

8

Comprar

10

Mantener

1

Vender

Puntuación técnica

By Trading Central

59.52 / 62.66Soporte y Resistencia

Corto Plazo

Bullish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation
help-icon Live chat